Chugai pharmaceutical's sales share 2022, by disease area
In the fiscal year 2022, the Japanese company Chugai Pharmaceutical Co., Ltd stated that approximately 37 percent of their total sales derived from products made for overseas markets. Due to the EU's approval of "Actemra" as a COVID-19 treatment, this segment has outperformed Chugai's domestic oncological product range.